Eligible patients were aged 18 years or older, able to give written informed consent, and scheduled (independently from this study) to have a liver biopsy for investigation of suspected NAFLD (usually as a result of abnormal liver enzymes and an ultrasound scan showing an echobright liver) within 2 weeks before or after LSM by VCTE and CAP measurements. All patients gave written informed consent to participate in the study. Eligible patients were negative for hepatitis B surface antigen, anti-hepatitis C virus antibody, hepatitis C virus RNA, and hepatitis B virus DNA. Patients were excluded in case of ascites, pregnancy, active implantable medical device (such as pacemaker or defibrillator), liver transplantation, cardiac failure or clinically significant valvular disease, haemochromatosis, refusal to have liver biopsy or blood tests, alcohol consumption above recommended limits (>14 units per week for women and >21 units per week for men), diagnosis of active malignancy or other terminal disease, or participation in another clinical trial within the previous 30 days. Age, sex, body-mass index (BMI), and presence of diabetes, hypertension, and hypercholesterolaemia were recorded for each patient. A 12 h fasting blood sample was obtained locally and then shipped to a central laboratory for assessment.
Newsome P.N., Sasso M., Deeks J.J., Paredes A., Boursier J., Chan W.K., Yilmaz Y., Czernichow S., Zheng M.H., Wong V.W., Allison M., Tsochatzis E., Anstee Q.M., Sheridan D.A., Eddowes P.J., Guha I.N., Cobbold J.F., Paradis V., Bedossa P., Miette V., Fournier-Poizat C., Sandrin L, & Harrison S.A. (2020). FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet. Gastroenterology & Hepatology, 5(4), 362-373.
Publication 2020
AscitesBiopsyBlood Blood tests Body mass index Cardiac failure Defibrillator DiabetesDiagnosisEnzymes Haemochromatosis Hepatitis b surface antigen Hepatitis b virusHepatitis c virus Hepatitis c virus antibody Hypercholesterolaemia HypertensionLiver Liver transplantation Malignancy Medical device Nafld PacemakerPatientsPregnancy Ultrasound scan Women
Corresponding Organization : University of Birmingham
Other organizations :
Joint Base San Antonio, San Antonio Military Medical Center, Uniformed Services University of the Health Sciences, Université d'Angers, University of Malaya, Marmara University, Université Paris Cité, Hôpital Européen Georges-Pompidou, Assistance Publique – Hôpitaux de Paris, Wenzhou Medical University, First Affiliated Hospital of Wenzhou Medical University, Chinese University of Hong Kong, Cambridge University Hospitals NHS Foundation Trust, University College London, The Royal Free Hospital, Newcastle University, Newcastle upon Tyne Hospital, NIHR Newcastle Biomedical Research Centre, University of Plymouth, University of Nottingham, Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust, University of Oxford, John Radcliffe Hospital, Oxford BioMedica (United Kingdom), Hôpital Beaujon, Régie Autonome des Transports Parisiens (France)
Negative for hepatitis B surface antigen, anti-hepatitis C virus antibody, hepatitis C virus RNA, and hepatitis B virus DNA
Absence of ascites, pregnancy, active implantable medical device, liver transplantation, cardiac failure or clinically significant valvular disease, haemochromatosis, active malignancy or other terminal disease, or participation in another clinical trial within the previous 30 days
Alcohol consumption within recommended limits (≤14 units per week for women and ≤21 units per week for men)
12 h fasting blood sample
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to
get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
